Advances in the Research of Har-Gabur Fluorescent Carbon Dots for the Treatment of Hepatocellular Carcinoma

DOI: https://doi.org/10.62517/jmhs.202605225

Author(s)

Wurihan1, Tegexibaiyin Wang2,*, Qingshan Zhang3,*

Affiliation(s)

Wurihan1, Tegexibaiyin Wang2,*, Qingshan Zhang3,* ¹Inner Mongolia Medical University, Hohhot, Inner Mongolia, China ²Affiliated Hospital of Inner Mongolia Minzu University, Tongliao, Inner Mongolia, China ³Inner Mongolia Minzu University, Tongliao, Inner Mongolia, China *Corresponding authors

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive and lethal cancer that often faces problems such as drug resistance and tumor recurrence. Mongolian medicine is an important part of the traditional ethnic medicine of China, and is practiced for thousands of years by the Mongolian people. Har-Gabur (calcined animal feces in traditional medicine) is one of the key components of “Po Pi” (breaking stagnation) therapy with a long history and potential pharmacological activity against hepatic diseases. In recent times, carbon quantum dots (CQDs) have garnered a considerable amount of attention due to their ultrasmall size, high surface area, superb biocompatibility, easy surface functionalization and unique optical properties, making them promising nanoplatforms for various biomedical applications. The review summarizes the chemical composition, pharmacological activity and anti-HCC potential of Har-Gabur and the nanoengineered products, namely fluorescent carbon dots derived from Har-Gabur, aiming to provide insights on new approaches of nanoengineering Mongolian Har-Gabur for HCC treatment, and to give a theoretical basis and research directions to support modernization and application of traditional Mongolian medicine.

Keywords

Carbon Quantum Dots; Har-Gabur Carbon Dots; Mongolian Medicine; Hepatocellular Carcinoma

References

[1]Chan S, Sun H, Xu Y et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. The Lancet, 2025; 406, 731-778. [2]Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024; 74:229-263. [3]National Health Commission of the People’s Republic of China. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition). Electronic Journal of Comprehensive Oncology Treatment, 2024, 10(3) [4]Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023 Dec; 20(12):864-884. [5]Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 Jan 21;7(1):6. [6]Salazar J, Le A. The Heterogeneity of Liver Cancer Metabolism. Advances in Experimental Medicine and Biology, 2021: 127-136. [7]Yang H, Cheng J, Zhuang H, et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell, 2024, 42(4): 535-551.e8. [8]Cheng K, Cai N, Zhu J, et al. Tumor-associated macrophages in liver cancer: From mechanisms to therapy. Cancer Communications (London, England), 2022, 42(11): 1112-1140. [9]Taniguchi H. Liver Cancer 2.0. International Journal of Molecular Sciences, 2023, 24(24): 17275. [10]Bayda S, Adeel M, Tuccinardi T, et al. The history of nanoscience and nanotechnology: From chemical-physical applications to nanomedicine. Molecules (Basel, Switzerland), 2019, 25(1): 112. [11]Desai N, Rana D, Patel M, et al. Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape. Small, 2025, 21(29). [12]Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, Wang K, Xu J, Cheng Y, Gao X. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024 Aug 12;9(1):200. [13]Cai Y, Wang W, Jiao Q, et al. Nanotechnology for the diagnosis and treatment of liver cancer. International Journal of Nanomedicine, 2024, 19: 13805-13821. [14]Cheng J, Huang H, Chen Y, Wu R. Nanomedicine for Diagnosis and Treatment of Atherosclerosis. Adv Sci (Weinh). 2023 Dec; 10(36):e2304294. [15]Yang H, Tan H, Wen H, Xin P, Liu Y, Deng Z, Xu Y, Gao F, Zhang L, Ye Z, Zhang Z, Chen Y, Wang Y, Sun J, Lam JWY, Zhao Z, Kwok RTK, Qiu Z, Tang BZ. Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer's Diseases. ACS Nano. 2024 Dec 17;18(50):33792-33826. [16]Ladju R B, Ulhaq Z S, Soraya G V. Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma. World Journal of Gastroenterology, 2022, 28(2): 176-187. [17]Cai L, Du Y, Xiong H, et al. Application of nanotechnology in the treatment of hepatocellular carcinoma. Frontiers in Pharmacology, 2024, 15. [18]Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics, 2021, 14(1): 41. [19]Mocci F, de Villiers Engelbrecht L, Olla C, Cappai A, Casula MF, Melis C, Stagi L, Laaksonen A, Carbonaro CM. Carbon Nanodots from an In Silico Perspective. Chem Rev. 2022 Aug 24;122(16):13709-13799. [20]Wuyuntu, Wu Siqinbilige, and Baolezhaolu. Review of Mongolian-specific medicine Hei-Bing-Pian. China Journal of Traditional Chinese Medicine and Pharmacy, 2016, 31(09): 3672-3675. [21]Du Laina. Research on Early Diagnosis Technology of Hepatocellular Carcinoma Using Har-Gabur Fluorescent Carbon Dots Coupled with GPC-3 Antibody. Inner Mongolia Medical University, 2020. [22]Yixi Balazhu’er. Ren Yao Bai Jing Jian. Hohhot: Inner Mongolia People’s Publishing House, 1998. (in Mongolian) [23]Editorial Committee of the Encyclopedia of Mongolian Studies. Encyclopedia of Mongolian Studies: Volume of Medicine. 1st ed. Hohhot: Inner Mongolia People’s Publishing House, 2012: 201. [24]Ce Surongzhabu, Qiren Wangqige. Internal Medicine of Mongolian Medicine. Hohhot: Inner Mongolia People’s Publishing House, 2011: 3. [25]Kang Shuanglong. Traditional Processing Methods of Mongolian Medicinal Materials. Hohhot: Yuanfang Publishing House, 2007: 80. [26]Zhao Yuying, Batu, Zhao Yuqin. Determination of Fe and other inorganic elements in Mongolian medicine Har-Gabur and its patent medicines and pharmacodynamic analysis. Journal of Medicine and Pharmacy of Chinese Minorities, 2000, 6(1): 44-45. [27]Du Laina, Tege Xibaiyin. Overview of the application of fluorescent carbon dots in modern research of Mongolian medicine. Journal of Medicine and Pharmacy of Chinese Minorities, 2018, 24(9): 60-62. [28]Ma Mengying, Zeng Wenhong, Guan Zhiyu, Lin Chunlian, Liu Jing, Huang Xiao, Zhu Ye, Yan Jie. Study on the Adsorption Performance of Mangolian Medicine Har Gabur. Journal of Jiangxi University of Traditional Chinese Medicine, 2019, 31(4): 66-68. [29]Li Fuquan, Chang Liang, Chen Guangrong, Jin Hui, Wei Yanpei, Bai Yinfu, Feng Guoqing, Liu Jing. Comparative study on endotoxin adsorption by Mongolian medicinal material Har-Gabur and activated carbon. Journal of Medicine and Pharmacy of Chinese Minorities, 2018, 24(2): 49-50. [30]Wu Ping, Yang Lei, Zhou Yiqun, Kuai Mengni, Peng Xutang, Zhang Zhiguo. Historical evolution and modern research on carbonizing by calcining in Chinese medicine. Acta Chinese Medicine and Pharmacology, 2022, 50(5): 109-114. [31]Lyu Y, Zhang HT, Guo WF, Liang H, Zhang L, Li X, Li MH. [Inheritance and development of traditional Mongolian medicine processing]. Zhongguo Zhong Yao Za Zhi. 2019 Jul;44(13):2742-2747. Chinese. [32]Sun L, Zhang R, Zhang T, Liu X, Zhao Y, Yang M, Cheng H, Zhang Q, Zhang Y, Wu X, Li B. Synthesis, applications and biosafety evaluation of carbon dots derived from herbal medicine. Biomed Mater. 2023 Jun 26;18(4). [33]Zhao Y, Li Y, Li D, Yuan H, Shen C. Eco-Friendly Synthesized Carbon Dots from Chinese Herbal Medicine: A Review. Int J Nanomedicine. 2025 Mar 12; 20:3045-3065. [34]Zeng M, Wang Y, Liu M, Wei Y, Wen J, Zhang Y, Chen T, He N, Fan P, Dai X. Potential Efficacy of Herbal Medicine-Derived Carbon Dots in the Treatment of Diseases: From Mechanism to Clinic. Int J Nanomedicine. 2023 Nov 9; 18:6503-6525. [35]Mokoloko L L, Forbes R P, Coville N J. The Transformation of 0-D Carbon Dots into 1-, 2- and 3-D Carbon Allotropes: A Minireview. Nanomaterials, 2022, 12(15): 2515. [36]Cao Qun. Isolation and Antibacterial Properties of Carbon Nanoparticles from Mongolian Medicine Har-Gabur. Inner Mongolia Medical University, 2020. [37]Ye Rigui. Study on Active Components of Glycyrrhiza Leaves and Quantification of Bile Acids in Animal Medicinal Materials such as Har-Gabur. Inner Mongolia University, 2016. [38]Shiffka SJ, Kane MA, Swaan PW. Planar bile acids in health and disease. Biochim Biophys Acta Biomembr. 2017 Nov;1859(11):2269-2276. [39]Wang Yuguang. Determination of Iron Content in Mongolian Medicine Har-Gabur by Spectrophotometry. Journal of Inner Mongolia Finance and Economics College (Comprehensive Edition), 2009, 7(6): 86-88. DOI:10.13895/j.cnki.jimufe.2009.06.018. [40]Xu Xiuting, Zhao Yuying, Bai Shuzhen, et al. Photometric Determination of Microamounts of Manganese in the Mongolia Drug "Hei-bing-pian". Physical Testing and Chemical Analysis Part B: Chemical Analysis, 2008, 44(12): 1114-1116. [41]Xiao X, Chen B, Chen Z, Zhu L, Schnoor JL. Insight into Multiple and Multilevel Structures of Biochars and Their Potential Environmental Applications: A Critical Review. Environ Sci Technol. 2018 May 1;52(9):5027-5047. [42]Xing Jiehong, Yue Jingzhuo, Liu Qingling. Determination of nitrogen content in Mongolian heibingpian. Journal of Northern Pharmacy, 2022, 19(2): 18-20. [43]Wang Huan. Construction of Carbon Nanomaterials Enriched with Specific Oxygen-Containing Functional Groups and Their Biomedical Applications. University of Science and Technology of China, 2020. [44]Hu Y, Gao M, Chenghuang J, Bao R. Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma. Front Pharmacol. 2025 May 19; 16:1595853. [45]Luo W, Guo S, Zhou Y, Zhao J, Wang M, Sang L, Chang B, Wang B. Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy. Front Microbiol. 2022 Apr 27; 13:873160. [46]He, G., Karin, M. NF-κB and STAT3 – key players in liver inflammation and cancer. Cell Res 21, 159–168 (2011). [47]Lin Jing, Chang Liang, Bai Yinfu, et al. Effect Research of Black Spar of Special Mongolia Herbal for Experimental Clitis in Rats. Journal of Medicine and Pharmacy of Chinese Minorities, 2009, 15(4): 40-42. [48]Cai Fang, Chen Guangrong, Bai Yinfu. Effect of Har-Gabur on intestinal smooth muscle function in animals. Journal of Medicine and Pharmacy of Chinese Minorities, 2008(3): 59-60. [49]Siqing Tunala, Li Yongmei, Liu Lei. Experimental study on anti-Helicobacter pylori effects of Mongolian medicine Wuwei Qingzhuo Powder and Shiwei Heibingpian Powder. Chinese Journal of Experimental Diagnostics, 2016, 20(9): 1546-1547. [50]Cao Qingqing. Study on the Effect of Astragaloside IV Combined with Carbon Nanoparticles on Fas/FasL Pathway in Gastric Ulcer. Hebei University of Science and Technology, 2019. [51]Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14. [52]Hu Y, Gao M, Chenghuang J, Bao R. Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma. Front Pharmacol. 2025 May 19; 16:1595853. [53]Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018 Mar; 19(3):222-232. [54]Yuan X et al. Cellular Toxicity and Immunological Effects of Carbon-based Nanomaterials. Particle and Fibre Toxicology. 2019;16(1). [55]Zhang D, Feng F, Li Q, Wang X, Yao L. Nanopurpurin-based photodynamic therapy destructs extracellular matrix against intractable tumor metastasis. Biomaterials. 2018 Aug; 173:22-33. [56]Hsu CJ, Wu MH, Chen CY, Tsai CH, Hsu HC, Tang CH. AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma. Cell Commun Signal. 2013 Sep 18; 11:68. Piao H, Jiang Y, Jin S, Shi J, Yu J, Wang W, Du Z, Yao H, Liu Q, Li N, Fu J, Shen Y, Li M. Modulation of the immune microenvironment using nanomaterials: a new strategy for tumor immunotherapy. Front Immunol. 2025 Jul 2; 16:1614640.